Previous Close | 154.70 |
Open | 155.66 |
Bid | 0.00 x 800 |
Ask | 0.00 x 800 |
Day's Range | 154.53 - 155.86 |
52 Week Range | 95.02 - 155.86 |
Volume | |
Avg. Volume | 1,441,591 |
Market Cap | 348.992B |
Beta (5Y Monthly) | 0.33 |
PE Ratio (TTM) | 53.16 |
EPS (TTM) | 2.92 |
Earnings Date | N/A |
Forward Dividend & Yield | 1.77 (1.27%) |
Ex-Dividend Date | Mar 24, 2023 |
1y Target Est | 140.39 |
Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.
Bagsværd, Denmark, 27 March 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme i
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.